&w=3840&q=100)
Can a broken heart really kill you? Science says yes — here's why
Researchers outlined five distinct grief patterns following bereavement, with those in the most severe category facing a higher likelihood of dying within a decade. Representational Image/Pixabay
The death of someone deeply loved is one of life's most painful experiences.
But beyond the emotional toll, new research suggests that grief can actually shorten lives.
A decade-long study from Denmark has found that people enduring the most severe and unrelenting grief were far more likely to die within 10 years of their bereavement than those who coped with it more mildly.
Published in the journal Frontiers in Public Health, the research tracked the health of more than 1,700 bereaved individuals for a decade and concluded that grief isn't just an emotional wound — it can trigger a cascade of physical consequences that may ultimately be fatal.
STORY CONTINUES BELOW THIS AD
Tracking grief over a decade
Beginning in 2012, researchers at Aarhus University in Denmark recruited 1,735 people who had recently lost a loved one — most were women, and their average age was 62.
Nearly two-thirds of participants had lost a partner, 27 per cent had lost a parent, and about seven percent had experienced the death of another close relative.
The participants were asked to complete detailed surveys on their grief when they enrolled, then again after six months, and once more after three years.
These questionnaires helped scientists categorise the severity of their grief over time and to observe how their symptoms evolved or persisted.
The researchers identified five distinct grief patterns, or 'trajectories':
Persistently low symptoms – 38 per cent of participants displayed relatively mild grief responses that didn't disrupt daily life significantly.
High but easing symptoms – 18 per cent started with intense grief that gradually diminished.
Moderate but easing symptoms – 29 per cent had mid-range symptoms that lessened over time.
Delayed peak symptoms – 9 per cent began with lower levels of grief, which spiked about six months after the loss before tapering off.
Persistent high symptoms – 6 per cent remained at consistently elevated levels of grief with little or no relief.
It was this last group that faced the gravest risks.
The numbers paint a stark picture
Over the 10-year follow-up, researchers found that 26.5 per cent of those in the 'high grief' group had died, compared to just 7.3 per cent in the group with the lowest grief symptoms.
Those with the most unrelenting sorrow had an 88 per cent higher mortality risk than those with milder grief.
The study also found that participants suffering from persistent grief were far more likely to be prescribed antidepressants and to continue mental health therapy years after their loss.
Their reliance on primary care and psychiatric services was notably higher in the first three years — though by year seven, these differences began to level off.
Researchers stressed that the study didn't determine the exact causes of death among the bereaved. But it strongly reinforces previous evidence that intense emotional distress can lead to serious health consequences.
STORY CONTINUES BELOW THIS AD
'We have previously found a connection between high grief symptom levels and higher rates of cardiovascular disease, mental health problems, and even suicide. But the association with mortality should be further investigated,' said Dr. Mette Kjærgaard Nielsen, a postdoctoral researcher at Aarhus University and a coauthor of the study, said in a statement.
How grief impacts the body
Grief triggers stress responses that can damage the body over time. One well-documented condition, broken heart syndrome — also called stress-induced cardiomyopathy or Takotsubo cardiomyopathy — can appear suddenly after an intense emotional event, such as the loss of a loved one.
In this condition, the heart temporarily enlarges and struggles to pump blood efficiently, creating symptoms that can be mistaken for a heart attack.
While broken heart syndrome is more commonly diagnosed in women, men who experience it have a higher likelihood of dying from the condition, according to a separate study published earlier this year in the Journal of the American Heart Association.
But the effects of grief are not limited to acute heart failure. Prolonged sorrow can lead to elevated blood pressure, chronic inflammation, disrupted hormone levels such as cortisol, and a weakened immune system.
Previous research has shown that bereaved spouses and partners face higher risks of dying from heart disease or suicide in the first three years after their loss. For men, there is also an elevated risk of fatal respiratory or digestive issues.
STORY CONTINUES BELOW THIS AD
Identifying those most vulnerable
The research also shed light on who might be at greatest risk.
Many in the 'high grief' category already showed signs of mental health fragility before their loss, with a higher likelihood of having been prescribed psychiatric medications.
'That suggests that they had signs of mental vulnerability which may cause greater distress on bereavement,' Nielsen explained.
This insight could help doctors intervene earlier. 'A GP could look for previous signs of depression and other severe mental health conditions,' Nielsen said.
'They can then offer these patients tailored follow-up in general practice, or refer them to a private practice psychologist or secondary care. The GP may also suggest a bereavement follow-up appointment focusing on mental health.'
Can therapy change the outcome?
The study did not evaluate whether therapy or counselling reduced the likelihood of early death among the most grief-stricken participants.
But Nielsen believes there is value in seeking help: 'I would say that they may benefit from specific grief therapy.'
Grief therapy, support groups, and structured bereavement follow-ups may help blunt the long-term harm that chronic grief inflicts.
Researchers say this is an area that warrants further investigation.
Also Watch:
With inputs from agencies

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Economic Times
7 hours ago
- Economic Times
Novo Nordisk CEO warns of layoffs as Wegovy challenge heats up
Synopsis Novo Nordisk warned of ongoing competition from copycat versions of its obesity drug Wegovy and signaled possible layoffs due to slowing sales growth, especially in the U.S. The Danish drugmaker, which lost $95 billion in market value after cutting full-year forecasts, said over one million Americans still use compounded GLP-1 drugs despite a U.S. ban. Reuters Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could face layoffs as it battles rising pressure from main U.S. rival Eli Lilly, the Danish drugmaker warned on Wednesday. Novo, which became Europe's most valuable company worth $650 billion last year on booming sales of Wegovy, is facing a pivotal moment as the medicine loses market share and sees sales growth slow, especially in the United States. It has warned of far slower growth this year - in part due to compounders who have been allowed to make copycat medicines based on the same ingredients as Wegovy due to shortages. Novo cut its full-year sales and profit forecasts last week, wiping $95 billion off its market value since. The shares were down 3.4% at 1350 GMT. The slide is a huge and abrupt turnaround for the firm that has been one of the world's hottest investment stories, which led to a rapid expansion of manufacturing and sales capacity. Now the firm is eyeing potential cost-cutting measures. "We probably won't be able to avoid layoffs," outgoing CEO Lars Fruergaard Jorgensen told Danish broadcaster DR. "When you have to adjust a company, there are some areas where you have to have fewer people, some (areas) where you have to be smaller." He added, though, that any decision on layoffs would be in the hands of the incoming CEO, company veteran Maziar Mike Doustdar, who takes over on Thursday. On a media call, Jorgensen said the market for copycat versions of Wegovy's class of drugs - known as GLP-1 receptor agonists - was of "equal size to our business" and compounded versions of Wegovy were sold at a "much lower price point". In May, the company said it expected many of the roughly one million U.S. patients using compounded GLP-1 drugs to switch to branded treatments after a U.S. Food and Drug Administration ban on compounded copies of Wegovy took effect on May 22, and it expected compounding to wind down in the third quarter. However, finance chief Karsten Munk Knudsen said on Wednesday that more than one million U.S. patients were still using compounded GLP-1s and that Novo's lowered outlook has "not assumed a reduction in compounding" this year. "The obesity market is volatile," Knudsen told analysts when asked under what circumstances the company could see negative growth in the last six months of the year. The low end of Novo's new full-year guidance range would be for "unforeseen events", such as stronger pricing pressure in the U.S. than forecast, he said. The lower end of the range would imply sales around 150 billion Danish crowns ($23 billion) in the second half of 2025, compared with 157 billion in the same period last year. ENCOURAGING PRESCRIPTION DATA Knudsen reiterated that the company was pursuing multiple strategies, including lawsuits against compounding pharmacies, to halt unlawful mass compounding. Jorgensen said the company was encouraged by the latest U.S. prescription data for Wegovy. While the drug was overtaken earlier this year by rival Lilly's Zepbound in terms of U.S. prescriptions, that lead has narrowed in the past month. Second-quarter sales of Wegovy rose by 36% in the U.S. and more than quadrupled in markets outside the U.S. compared to a year ago, Novo said. While Wegovy's U.S. pricing held steady in the quarter, the company expected deeper erosion in the key U.S. market in the second half, due to a greater portion of sales expected from the direct-to-consumer or cash-pay channel, as well as higher rebates and discounts to insurers, Knudsen said. He said Novo was expanding its U.S. direct-to-consumer platform, NovoCare, launched in March, and may need to pursue similar "cash sales" directly to patients, outside of insurance channels, in some markets outside the United States. COST CUTS The company reiterated its full-year earnings expectations on Wednesday after last week's profit warning. Jorgensen said Novo was acting to "ensure efficiencies in our cost base" as the company announced it would terminate eight R&D projects. "There seems to be a larger R&D clean-out than usual, but we do not know if this reflects a strategic re-assessment or just a coincidence," Jefferies analysts said in a note. Investors have questioned whether Novo can stay competitive in the booming weight-loss drug market. Several equity analysts have cut their price targets and recommendation on the stock since last week. Shares in Novo plunged 30% last week - their worst weekly performance in over two decades. Sales rose 18% in the second quarter to 76.86 billion Danish crowns, below analysts' initial expectations.


Time of India
7 hours ago
- Time of India
Novo Nordisk CEO warns of layoffs as Wegovy challenge heats up
Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could face layoffs as it battles rising pressure from main U.S. rival Eli Lilly , the Danish drugmaker warned on Wednesday. Novo, which became Europe's most valuable company worth $650 billion last year on booming sales of Wegovy, is facing a pivotal moment as the medicine loses market share and sees sales growth slow, especially in the United States. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program It has warned of far slower growth this year - in part due to compounders who have been allowed to make copycat medicines based on the same ingredients as Wegovy due to shortages. Novo cut its full-year sales and profit forecasts last week, wiping $95 billion off its market value since. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Affordable Pre-Owned Jewelry in Great Condition in Malaysia Rings | Search Ads Search Now Undo The shares were down 3.4% at 1350 GMT. The slide is a huge and abrupt turnaround for the firm that has been one of the world's hottest investment stories, which led to a rapid expansion of manufacturing and sales capacity. Now the firm is eyeing potential cost-cutting measures. Live Events "We probably won't be able to avoid layoffs," outgoing CEO Lars Fruergaard Jorgensen told Danish broadcaster DR. "When you have to adjust a company, there are some areas where you have to have fewer people, some (areas) where you have to be smaller." He added, though, that any decision on layoffs would be in the hands of the incoming CEO, company veteran Maziar Mike Doustdar, who takes over on Thursday. On a media call, Jorgensen said the market for copycat versions of Wegovy's class of drugs - known as GLP-1 receptor agonists - was of "equal size to our business" and compounded versions of Wegovy were sold at a "much lower price point". In May, the company said it expected many of the roughly one million U.S. patients using compounded GLP-1 drugs to switch to branded treatments after a U.S. Food and Drug Administration ban on compounded copies of Wegovy took effect on May 22, and it expected compounding to wind down in the third quarter. However, finance chief Karsten Munk Knudsen said on Wednesday that more than one million U.S. patients were still using compounded GLP-1s and that Novo's lowered outlook has "not assumed a reduction in compounding" this year. "The obesity market is volatile," Knudsen told analysts when asked under what circumstances the company could see negative growth in the last six months of the year. The low end of Novo's new full-year guidance range would be for "unforeseen events", such as stronger pricing pressure in the U.S. than forecast, he said. The lower end of the range would imply sales around 150 billion Danish crowns ($23 billion) in the second half of 2025, compared with 157 billion in the same period last year. ENCOURAGING PRESCRIPTION DATA Knudsen reiterated that the company was pursuing multiple strategies, including lawsuits against compounding pharmacies, to halt unlawful mass compounding. Jorgensen said the company was encouraged by the latest U.S. prescription data for Wegovy. While the drug was overtaken earlier this year by rival Lilly's Zepbound in terms of U.S. prescriptions, that lead has narrowed in the past month. Second-quarter sales of Wegovy rose by 36% in the U.S. and more than quadrupled in markets outside the U.S. compared to a year ago, Novo said. While Wegovy's U.S. pricing held steady in the quarter, the company expected deeper erosion in the key U.S. market in the second half, due to a greater portion of sales expected from the direct-to-consumer or cash-pay channel, as well as higher rebates and discounts to insurers, Knudsen said. He said Novo was expanding its U.S. direct-to-consumer platform, NovoCare, launched in March, and may need to pursue similar "cash sales" directly to patients, outside of insurance channels, in some markets outside the United States. COST CUTS The company reiterated its full-year earnings expectations on Wednesday after last week's profit warning. Jorgensen said Novo was acting to "ensure efficiencies in our cost base" as the company announced it would terminate eight R&D projects. "There seems to be a larger R&D clean-out than usual, but we do not know if this reflects a strategic re-assessment or just a coincidence," Jefferies analysts said in a note. Investors have questioned whether Novo can stay competitive in the booming weight-loss drug market. Several equity analysts have cut their price targets and recommendation on the stock since last week. Shares in Novo plunged 30% last week - their worst weekly performance in over two decades. Sales rose 18% in the second quarter to 76.86 billion Danish crowns, below analysts' initial expectations.
&w=3840&q=100)

First Post
12 hours ago
- First Post
Rare pneumonia-like illness kills 3 in New York City: What is Legionnaires' disease? Is it deadly?
Three people have died and 67 others have been diagnosed with Legionnaires' disease in New York City in recent weeks. The illness, a type of pneumonia caused by Legionella bacteria, mainly affects people over 50, smokers, and those with chronic lung issues or weakened immunity read more Three people have died and 67 others have been diagnosed with Legionnaires' disease in New York City's Harlem in recent weeks. Those at greater risk include people over the age of 50, smokers, and individuals with weakened immune systems or long-term breathing problems. Health authorities have advised them to take extra care. ALSO READ | Ditch that soda and noodles. The lung cancer link to ultra-processed foods Officials say the outbreak in Central Harlem is connected to cooling towers. These are large units that use water and fans to help cool buildings. STORY CONTINUES BELOW THIS AD But what exactly is this pneumonia-like illness? What symptoms should people look out for, and how is it treated? Let's take a look: What is Legionnaires' disease? Legionnaires' disease is a form of pneumonia caused by Legionella bacteria. These bacteria grow in warm water and can spread through building water systems. Common sources include showerheads, hot tubs and cooling towers. People usually catch the illness by breathing in small droplets of contaminated water. Hospital patients can also get infected through tainted water or ice, and babies may be exposed during water births, according to health officials. The disease does not spread from person to person. It mainly affects the lungs but can also harm the brain and digestive system. In some cases, it can be life-threatening. Stomach pain is one of the symptoms. Pixabay/Representational Image Although not very common, Legionnaires' disease has been reported more often in recent years. According to the US Centers for Disease Control and Prevention, the number of cases has gone up nearly nine times since 2000. In the Harlem outbreak, health officials have linked the source to cooling towers. So far, 11 towers have tested positive for the bacteria. These towers help cool large systems like central air conditioning and refrigeration. Authorities have assured residents in the affected areas that their tap water is safe. They can continue to shower, bathe, cook and use air conditioners at home. STORY CONTINUES BELOW THIS AD Symptoms of Legionnaires' disease Legionnaires' disease usually develops two to 14 days after contact with the bacteria and causes symptoms similar to pneumonia. Common symptoms include: Fever Muscle aches Cough (often dry) Shortness of breath Headache Nausea Diarrhoea Stomach pain Confusion Coughing up blood While it mostly affects the lungs, the infection can also spread to wounds and other parts of the body, including the heart. ALSO READ | Is it safe to boil water more than once? Can it be treated? Yes. Legionnaires' disease is treated with antibiotics. These may be given through a drip or as tablets, depending on the condition of the patient, according to Cleveland Clinic. If breathing becomes difficult, doctors may provide oxygen support. Most people need hospital care while being treated. 'Legionnaires' disease can be effectively treated if diagnosed early, but New Yorkers at higher risk, like adults aged 50 and older and those who smoke or have chronic lung conditions, should be especially mindful of their symptoms and seek care as soon as symptoms begin,' said acting Health Commissioner Dr Michelle Morse was quoted as saying by The New York Post. With early treatment, most people recover fully, though it may take a few weeks to feel completely well again. Officials say the outbreak in New York City's Central Harlem is connected to cooling towers. Reuters/File Photo How can Legionnaires' disease be prevented? According to the World Health Organization (Who), those in charge of maintaining buildings and water systems can help prevent Legionnaires' disease by limiting the growth of Legionella bacteria. This includes regularly cleaning and disinfecting cooling towers, keeping the right level of chlorine in spa pools and flushing unused taps at least once a week. There are also precautions people can take at home. Health officials in New York state recommend draining garden hoses, following cleaning and replacement instructions for water filters, checking chlorine levels in pools and hot tubs often and flushing hot water heaters twice a year. STORY CONTINUES BELOW THIS AD Is it deadly? Legionnaires' disease is a serious illness, but with the right treatment, most people recover. Lung infections caused by Legionella are fatal in about five to 10 per cent of treated cases. Without treatment, the risk of death rises sharply, with fatality rates ranging from 30 to 80 per cent. With inputs from agencies